Arcoris Bio, a Swiss life science research tools and in vitro diagnostics company based in Schlieren, has raised CHF 6.3 million in an oversubscribed seed financing round to support the commercialization and continued development of its MUSE biomarker detection platform. The funding round was co-led by Ventura Ace and ZEISS Ventures, with additional participation from Zürcher Kantonalbank and both new and existing private investors.
The company’s MUSE platform applies a nanotechnology-driven approach to enable simultaneous detection of multiple biomarkers with high sensitivity and operational simplicity. The funding will support the industrialization of the platform, the formation of new strategic partnerships, and the launch of additional product offerings aimed at broadening the technology’s impact in digital pathology workflows.
According to the company, the ability to measure multiple biomarkers in a single sample at higher throughput can significantly enhance research and clinical capabilities. This is seen as increasingly crucial as precision medicine, complex disease classification, and data-driven diagnostic methodologies continue to expand across the healthcare and pharmaceutical research sectors.
The financing represents a milestone for Arcoris Bio as it works to scale operations to meet growing industry demand and accelerate market entry. Investors highlighted the platform’s potential to address unmet needs in digital pathology and biomarker quantification, noting the technology’s applicability across various environments, including diagnostics, drug discovery, and precision medicine research.
KEY QUOTES:
“Attracting two lead investors with deep industry expertise is a strong validation of our technical and business strategy. This support empowers us in our mission of transforming biomarker detection and digital pathology.”
Simon Restrepo, Co-founder and CSO, arcoris bio
“Securing this financing marks a major milestone for arcoris bio. In a challenging market, we are grateful for the trust our investors have placed in our vision. Their support empowers us to bring our innovations to market faster, strengthen our operations, and scale to meet growing industry demand.”
Matyas Vegh, CEO, arcoris bio
“We have been impressed by the arcoris bio team’s vision and early traction with industry partners. We believe MUSE® represents a truly enabling technology for digital pathology.”
Andreas Jenne, Investment Director, Ventura Ace
“arcoris bio’s MUSE® technology fills a critical gap in the market to enable better diagnostics and applications like drug discovery or precision medicine. Its universal applicability is particularly exciting – MUSE® acts like a molecular GPU, amplifying the capabilities of existing biomarker platforms and opening new paths for innovation.”
Benedikt Klaes, Senior Investment Manager, ZEISS Ventures
